SYSTEMIC LUPUS ERYTHEMATOSUS

This phase 3 study tests whether upadacitinib, a drug already approved for other autoimmune diseases, can safely control moderate-to-severe lupus. About 1,000 adults with lupus will take either the drug or a placebo daily for a year, with some continuing for up to two more years.…

This study tests whether N-acetylcysteine (NAC), a supplement, can help control lupus, a chronic disease where the immune system attacks the body. About 290 adults with lupus will first take NAC for 3 months to find a safe dose, then half will continue NAC and half will get a pla…

This early-phase study tests a new treatment called RD06-04, which uses a patient's own immune cells modified to target and destroy harmful B cells. It aims to see if this approach is safe and tolerable for people with active autoimmune diseases like lupus, scleroderma, and Sjogr…

This study tests whether a monthly injection of anifrolumab can better control moderate-to-severe lupus compared to a placebo, when added to standard treatments. About 367 adults with active lupus took part. The goal is to see if the drug reduces disease activity and flare-ups wi…

This early-phase study tests NKX019, a type of immune cell therapy designed to target and calm the overactive immune system in people with lupus. About 6 adults with moderate to severe lupus, with or without kidney inflammation, will receive the treatment after a short chemothera…

This study looks at the long-term safety of enpatoran, an oral medication, for people with lupus (a chronic autoimmune disease). It includes 379 participants who already completed a 24-week treatment in a previous study. The goal is to monitor side effects and lab changes over up…

This early-phase study is testing a new treatment called KITE-363 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathy that haven't improved with standard therapies. KITE-363 uses a patient's own immune cells, which are modified in a lab t…

This study tests a new treatment called YTB323 for people with severe lupus that hasn't responded to other therapies. About 21 adults will receive this cell therapy to see if it is safe and helps control the disease. The goal is to manage lupus symptoms and reduce disease activit…

This study tests a new, non-invasive approach using low-frequency electromagnetic waves to help regulate the immune system in people with autoimmune diseases like lupus, rheumatoid arthritis, or multiple sclerosis. Over 12 weeks, participants receive either real or placebo sessio…

This study tests a new drug called MIL62 in 120 adults with systemic lupus erythematosus (SLE), an autoimmune disease. The goal is to see if MIL62 can reduce lupus disease activity better than a placebo. Participants must have active lupus and be on a stable treatment plan. The m…

This early-stage study tests whether a special type of immune cell, called a CAR-T cell, is safe for people with severe lupus that hasn't improved with standard treatments. About 22 participants aged 5 and older will receive these cells and be monitored for side effects and signs…

This early-stage study tests a new treatment called SC291 for people with severe lupus or vasculitis that hasn't responded to other therapies. SC291 uses specially designed immune cells from a donor to target and destroy faulty immune cells causing the disease. The main goal is t…

This study looks at the long-term safety of a drug called dapirolizumab pegol for people with systemic lupus erythematosus (lupus). About 760 adults who completed an earlier related study will receive the drug and be monitored for side effects. The goal is to see if the drug is s…

This phase 3 study tests whether adding a monthly injection of ianalumab to standard lupus treatments can better control disease activity and prevent flares. About 288 people with active systemic lupus erythematosus (SLE) will receive either ianalumab or a placebo for comparison.…

This study tests an experimental drug called obinutuzumab in 303 people with active lupus. The goal is to see if adding this drug to standard treatment can better control lupus activity and reduce flares. Participants receive either obinutuzumab or a placebo, and researchers meas…

This study looks at how a drug called belimumab works in children aged 5 to 17 with lupus. The drug is given as a shot under the skin, along with standard treatments. The goal is to check the drug's safety and how the body processes it, to help manage lupus symptoms long-term.

This study follows about 550 people with lupus who are starting a new medication called anifrolumab. Researchers want to see how well the drug controls disease activity and improves quality of life in routine medical practice, not just in controlled trials. The goal is to give do…

This study looks back at medical records of 180 adults with lupus to compare two drugs: telitacicept and belimumab. The goal is to see which one better controls disease activity and has fewer side effects. Participants were already taking one of the drugs for at least 12 weeks. T…

This study tests a new treatment using donor immune cells (CAR T-cells) that are designed to target and destroy faulty immune cells causing lupus and scleroderma. The goal is to control these severe autoimmune diseases when other treatments have failed. 18 adults with relapsed or…

This study tests an oral medication called deucravacitinib against a placebo in about 513 people with active moderate-to-severe lupus. The goal is to see if the drug can reduce disease activity and improve symptoms like joint pain and skin rashes. Participants must have been diag…